Techno Trends
TechnoTrends provide comprehensive coverage of the innovations and inventions in pharma products and pharma technologies across the world. The up-to-date listing of latest pharmaceutical product news and technology trends in the global pharma industry, keeps you abreast with all the latest pharmaceutical innovations happening world over.
Imperial College London Introduces Casgevy New Therapy for the Blood Disorder Treatment
Imperial College London has recently unveiled an innovative gene therapy known as Casgevy, offering promising prospects as a potential treatment for two inherited blood disorders.
UVA Health Discovered New Vorasidenib Drug for Brain Tumour
UVA Health's research has unveiled the potential of vorasidenib in treating grade 2 IDH-mutant gliomas. This discovery marks a significant stride in identifying a promising drug that will positively impact patients
Palvella Therapeutics Developed First-of-its-kind QTORIN rapamycin™ for Microcystic Lymphatic Malformations
Palvella Therapeutics has developed QTORIN rapamycin™, a revolutionary treatment specifically designed to address Microcystic Lymphatic Malformations (Microcystic LMs).
Chimeric Therapeutics Unveils Novel CHM 2101 Cell Therapy for Advanced Gastrointestinal Cancers
Chimeric Therapeutics has introduced a groundbreaking therapy named CHM 2101, representing a pioneering CDH17 CAR T cell treatment engineered specifically for gastrointestinal cancers.
Amicus Therapeutics Developed Breakthrough Pombiliti™ Treatment for Pompe Disease
Amicus Therapeutics unveiled Pombiliti™, a groundbreaking combination of Cipaglucosidase alfa-ATGA and Opfolda™ 65mg capsules, designed to assist adults dealing with late-onset Pompe disease
I-Mab Introduced Novel Felzartamab Antibody for Primary Membranous Nephropathy
I-Mab has introduced groundbreaking antibody known as felzartamab. This investigational monoclonal antibody specifically targets CD38 and is being developed as a potential therapy
Alphamab Oncology Developed First-of-its-kind KN026 for the Treatment of Gastric Cancer
Alphamab Oncology had developed KN026, a first-of-its-kind HER2 bispecific antibody for the treatment of HER2-positive gastric cancer and gastroesophageal junction cancer.
Coherus BioSciences and Junshi Biosciences Introduced First-of-its-kind LOQTORZI™ for the Treatment of Metastatic Nasopharyngeal Carcinoma (NPC)
Coherus BioSciences and Junshi Biosciences have introduced LOQTORZI™ (toripalimab-tpzi) as a treatment option for nasopharyngeal carcinoma (NPC).
Bristol Myers Squibb Developed First-in class LPA1 Treatment for Progressive Pulmonary Fibrosis
Bristol Myers Squibb has developed BMS-986278, a potential first-in-class, oral, lysophosphatidic acid receptor 1 (LPA1) antagonist, for the treatment of progressive pulmonary fibrosis
ArriVent Biopharma Discovered First-of-its-kind Furmonertinib for the Treatment of Non-Small Cell Lung Cancer
ArriVent Biopharma has discovered first-of-its-kind furmonertinib for the treatment of specific type of lung cancer, namely non-squamous non-small cell lung cancer
